EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Aug. 8, 2006--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT - News), announced today results for the quarter and six months ended June 30, 2006. Total revenues for the second quarter of 2006 were $24.0 million as compared with $22.6 million for the second quarter of 2005, an increase of $1.4 million, or 6% due primarily to product sales of Oxandrin® in the U.S., the Company’s product used in the treatment of weight gain following involuntary weight loss related to disease or medical condition, and oral liquid pharmaceutical products in the company’s U.K. subsidiary, Rosemont Pharmaceuticals, Ltd. which was recently sold on August 4, 2006.
